| scholarly article | Q13442814 |
| P50 | author | Ethan Russo | Q29643545 |
| P2860 | cites work | Care and feeding of the endocannabinoid system: a systematic review of potential clinical interventions that upregulate the endocannabinoid system | Q21132308 |
| Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects | Q24606148 | ||
| Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia | Q24607361 | ||
| Autism-associated neuroligin-3 mutations commonly disrupt tonic endocannabinoid signaling | Q24621853 | ||
| β-Neurexins Control Neural Circuits by Regulating Synaptic Endocannabinoid Signaling | Q26269814 | ||
| Translational evidence for a role of endocannabinoids in the etiology and treatment of posttraumatic stress disorder | Q27026926 | ||
| Marijuana and migraine | Q69424165 | ||
| Endocannabinoids in chronic migraine: CSF findings suggest a system failure | Q79374957 | ||
| The endocannabinoids anandamide and 2-arachidonoylglycerol inhibit cholinergic contractility in the human colon | Q80812664 | ||
| Acute reduction of anandamide-hydrolase (FAAH) activity is coupled with a reduction of nociceptive pathways facilitation in medication-overuse headache subjects after withdrawal treatment | Q84304527 | ||
| The cannabinoid receptor agonist delta-9-tetrahydrocannabinol does not affect visceral sensitivity to rectal distension in healthy volunteers and IBS patients | Q84760172 | ||
| Endocannabinoids control spasticity in a multiple sclerosis model | Q28142626 | ||
| Endocannabinoids and food intake: newborn suckling and appetite regulation in adulthood | Q28241829 | ||
| Elevated brain cannabinoid CB1 receptor availability in post-traumatic stress disorder: a positron emission tomography study | Q28290553 | ||
| Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide | Q28362078 | ||
| Cannabinoids and the gastrointestinal tract | Q28365382 | ||
| Cannabis use in patients with fibromyalgia: effect on symptoms relief and health-related quality of life | Q28477857 | ||
| Clinical endocannabinoid deficiency (CECD): can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions? | Q31065598 | ||
| Delta-9-THC based monotherapy in fibromyalgia patients on experimentally induced pain, axon reflex flare, and pain relief | Q33249831 | ||
| Motion sickness, stress and the endocannabinoid system | Q33588600 | ||
| The neurobiology of cannabinoid analgesia | Q33720138 | ||
| Effects of anandamide in migraine: data from an animal model | Q33823790 | ||
| Central anandamide deficiency predicts stress-induced anxiety: behavioral reversal through endocannabinoid augmentation | Q33990629 | ||
| Cannabinoids for gastrointestinal diseases: potential therapeutic applications | Q34169100 | ||
| Wired to run: exercise-induced endocannabinoid signaling in humans and cursorial mammals with implications for the 'runner's high'. | Q34263245 | ||
| Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial. | Q34266560 | ||
| Cannabinoids in bipolar affective disorder: a review and discussion of their therapeutic potential | Q34418106 | ||
| An endocannabinoid mechanism for stress-induced analgesia. | Q34428429 | ||
| Gastrointestinal afferents as targets of novel drugs for the treatment of functional bowel disorders and visceral pain | Q34430659 | ||
| Survey of medicinal cannabis use among childbearing women: patterns of its use in pregnancy and retroactive self-assessment of its efficacy against 'morning sickness'. | Q34482721 | ||
| Palmitoylethanolamide normalizes intestinal motility in a model of post-inflammatory accelerated transit: involvement of CB₁ receptors and TRPV1 channels | Q34571380 | ||
| Cannabis, pain, and sleep: lessons from therapeutic clinical trials of Sativex, a cannabis-based medicine | Q34582005 | ||
| Nabilone for the treatment of pain in fibromyalgia | Q34584429 | ||
| The effects of nabilone on sleep in fibromyalgia: results of a randomized controlled trial | Q34614801 | ||
| Effect of cannabinoid receptor activation on spreading depression | Q34649359 | ||
| The rational management of fibromyalgia patients | Q34746349 | ||
| Cannabinoids in the treatment of glaucoma | Q34786852 | ||
| Prevention of Diet-Induced Obesity Effects on Body Weight and Gut Microbiota in Mice Treated Chronically with Δ9-Tetrahydrocannabinol | Q35860227 | ||
| Is there a role for the endocannabinoid system in the etiology and treatment of melancholic depression? | Q36251629 | ||
| Neurobiological Interactions Between Stress and the Endocannabinoid System. | Q36366731 | ||
| Structural requirements for 5-HT2A and 5-HT1A serotonin receptor potentiation by the biologically active lipid oleamide | Q36463167 | ||
| Failure to extinguish fear and genetic variability in the human cannabinoid receptor 1. | Q36589751 | ||
| Cannabinoid receptor 1 gene and irritable bowel syndrome: phenotype and quantitative traits | Q36699687 | ||
| Increased capsaicin receptor TRPV1-expressing sensory fibres in irritable bowel syndrome and their correlation with abdominal pain | Q36930795 | ||
| Modulating the endocannabinoid system in human health and disease--successes and failures | Q36933683 | ||
| Randomized pharmacodynamic and pharmacogenetic trial of dronabinol effects on colon transit in irritable bowel syndrome-diarrhea | Q37178858 | ||
| Reductions in circulating endocannabinoid levels in individuals with post-traumatic stress disorder following exposure to the World Trade Center attacks | Q37409877 | ||
| The endocannabinoid system and migraine | Q37721545 | ||
| Review article: probiotics for the treatment of irritable bowel syndrome--focus on lactic acid bacteria. | Q37973803 | ||
| Hypoactivity of the spinal cannabinoid system results in NMDA-dependent hyperalgesia. | Q38340750 | ||
| Comprehensive Review of Medicinal Marijuana, Cannabinoids, and Therapeutic Implications in Medicine and Headache: What a Long Strange Trip It's Been …. | Q38503842 | ||
| The Role and Importance of Small Fiber Neuropathy in Fibromyalgia Pain | Q38615410 | ||
| Effects of Medical Marijuana on Migraine Headache Frequency in an Adult Population. | Q38691453 | ||
| Sativex successfully treats neuropathic pain characterised by allodynia: a randomised, double-blind, placebo-controlled clinical trial | Q39327817 | ||
| Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial | Q39373693 | ||
| Cannabis for migraine treatment: the once and future prescription? An historical and scientific review. | Q40847313 | ||
| Fibromyalgia and headache. Failure of serotonergic analgesia and N-methyl-D-aspartate-mediated neuronal plasticity: their common clues | Q41734841 | ||
| Cannabinoid (CB(1)), GABA(A) and GABA(B) receptor subunit changes in the globus pallidus in Huntington's disease. | Q42454539 | ||
| Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models | Q42508054 | ||
| Anandamide acts as a vasodilator of dural blood vessels in vivo by activating TRPV1 receptors | Q43262264 | ||
| Fibromyalgia in the irritable bowel syndrome: studies of prevalence and clinical implications | Q43437812 | ||
| The endogenous cannabinoid system controls extinction of aversive memories | Q44085607 | ||
| Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors | Q44333170 | ||
| Repeated intranasal capsaicin applications to treat chronic migraine | Q44452962 | ||
| An endogenous cannabinoid tone attenuates cholera toxin-induced fluid accumulation in mice | Q44569535 | ||
| Anandamide is able to inhibit trigeminal neurons using an in vivo model of trigeminovascular-mediated nociception | Q44725378 | ||
| Initial experiences with medicinal extracts of cannabis for chronic pain: results from 34 'N of 1' studies | Q44850914 | ||
| Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms | Q45049153 | ||
| Widespread decrease of type 1 cannabinoid receptor availability in Huntington disease in vivo | Q45299326 | ||
| Symptom-related changes of endocannabinoid and palmitoylethanolamide levels in brain areas of R6/2 mice, a transgenic model of Huntington's disease | Q45305788 | ||
| Abuse potential of dronabinol (Marinol). | Q46392742 | ||
| High endogenous cannabinoid levels in the cerebrospinal fluid of untreated Parkinson's disease patients. | Q46456086 | ||
| Abnormalities in the cerebrospinal fluid levels of endocannabinoids in multiple sclerosis | Q46555462 | ||
| Degradation of endocannabinoids in chronic migraine and medication overuse headache | Q46688717 | ||
| Endocannabinoids in platelets of chronic migraine patients and medication-overuse headache patients: relation with serotonin levels | Q46899274 | ||
| A shot at migraine | Q48066849 | ||
| Inhibition of FAAH reduces nitroglycerin-induced migraine-like pain and trigeminal neuronal hyperactivity in mice | Q48211631 | ||
| Effects of a cannabinoid receptor agonist on colonic motor and sensory functions in humans: a randomized, placebo-controlled study | Q48223585 | ||
| Cannabinoid (CB1) receptor activation inhibits trigeminovascular neurons | Q48405359 | ||
| A Lecture on Lumbago: Its Lessons and Analogues: Delivered at the National Hospital for the Paralysed and Epileptic | Q48577362 | ||
| Fibromyalgia is common in patients with transformed migraine | Q48682127 | ||
| Endovanilloid control of pain modulation by the rostroventromedial medulla in an animal model of diabetic neuropathy | Q48845847 | ||
| Brain type 1 cannabinoid receptor availability in patients with anorexia and bulimia nervosa | Q49107300 | ||
| Fibromyalgia and migraine, two faces of the same mechanism. Serotonin as the common clue for pathogenesis and therapy. | Q51118057 | ||
| A double-blind trial of delta 9-tetrahydrocannabinol in primary anorexia nervosa | Q51853691 | ||
| The medicinal use of cannabis in the UK: results of a nationwide survey. | Q55040827 | ||
| On the Preparations of the Indian Hemp, or Gunjah (Cannabis Indica), Their Effects on the Animal System in Health, and Their Utility in the Treatment of Tetanus and Other Convulsive Diseases | Q58768952 | ||
| Variations in the cannabinoid receptor 1 gene predispose to migraine | Q60054567 | ||
| Rational management of fibromyalgia | Q60680851 | ||
| P433 | issue | 1 | |
| P921 | main subject | fibromyalgia | Q540571 |
| endocannabinoids | Q10483908 | ||
| P304 | page(s) | 154-165 | |
| P577 | publication date | 2016-07-01 | |
| P1433 | published in | Cannabis and cannabinoid research | Q27727510 |
| P1476 | title | Clinical Endocannabinoid Deficiency Reconsidered: Current Research Supports the Theory in Migraine, Fibromyalgia, Irritable Bowel, and Other Treatment-Resistant Syndromes | |
| P478 | volume | 1 |
| Q104100825 | Association between gestational cannabis exposure and maternal, perinatal, placental, and childhood outcomes |
| Q90341499 | Bioactive Lipids in Cancer, Inflammation and Related Diseases : Acute and Chronic Mild Traumatic Brain Injury Differentially Changes Levels of Bioactive Lipids in the CNS Associated with Headache |
| Q58596177 | Cannabis Therapeutics and the Future of Neurology |
| Q89526826 | Cannabis, One Health, and Veterinary Medicine: Cannabinoids' Role in Public Health, Food Safety, and Translational Medicine |
| Q91775177 | Cerebrospinal fluid endocannabinoid levels in Gilles de la Tourette syndrome |
| Q28071794 | Current Therapeutic Cannabis Controversies and Clinical Trial Design Issues |
| Q55280787 | Emerging Role of (Endo)Cannabinoids in Migraine. |
| Q94560704 | Irritable Bowel Syndrome: Manipulating the Endocannabinoid System as First-Line Treatment |
| Q91574934 | Marijuana Use in Pregnancy and While Breastfeeding |
| Q58554827 | Migraine, Cyclic Vomiting Syndrome, and Other Gastrointestinal Disorders |
| Q47141476 | Rare genetic variants in the endocannabinoid system genes CNR1 and DAGLA are associated with neurological phenotypes in humans. |
| Q89861376 | Targeting Peripherally Restricted Cannabinoid Receptor 1, Cannabinoid Receptor 2, and Endocannabinoid-Degrading Enzymes for the Treatment of Neuropathic Pain Including Neuropathic Orofacial Pain |
| Q64072053 | The Endocannabinoid System as a Target in Cancer Diseases: Are We There Yet? |
| Q90132901 | The Endocannabinoid System of Animals |
| Q42258328 | The Use of Cannabis for Headache Disorders |
| Q89036142 | [Cannabinoids in pain medicine] |
Search more.